middle.news
Next Science Secures ASX Waiver to Return Capital After $50M Asset Sale
1:01pm on Tuesday 23rd of December, 2025 AEDT
•
Healthcare
Read Story
Next Science Secures ASX Waiver to Return Capital After $50M Asset Sale
1:01pm on Tuesday 23rd of December, 2025 AEDT
Key Points
ASX grants waiver from Listing Rule 7.25 enabling capital return
Capital return follows $50 million asset sale to OSARTIS GmbH
Share price currently at 13.5 cents, expected to drop post-return
Shareholder approval sought at January 2026 extraordinary meeting
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Next Science (ASX:NXS)
OPEN ARTICLE